JP2007518682A5 - - Google Patents

Download PDF

Info

Publication number
JP2007518682A5
JP2007518682A5 JP2006519250A JP2006519250A JP2007518682A5 JP 2007518682 A5 JP2007518682 A5 JP 2007518682A5 JP 2006519250 A JP2006519250 A JP 2006519250A JP 2006519250 A JP2006519250 A JP 2006519250A JP 2007518682 A5 JP2007518682 A5 JP 2007518682A5
Authority
JP
Japan
Prior art keywords
ring
substituted
unsaturated heterocyclic
optionally substituted
heterocyclic ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006519250A
Other languages
English (en)
Other versions
JP2007518682A (ja
JP4717811B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2004/011311 external-priority patent/WO2005012321A1/en
Publication of JP2007518682A publication Critical patent/JP2007518682A/ja
Publication of JP2007518682A5 publication Critical patent/JP2007518682A5/ja
Application granted granted Critical
Publication of JP4717811B2 publication Critical patent/JP4717811B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Claims (1)

  1. 式I
    Figure 2007518682

    (式中、環Aおよび環Bは、(1)環Aが置換されていてもよい単環不飽和異項環であり、環Bが置換されていてもよい単環不飽和異項環、置換されていてもよい二環縮合不飽和異項環、または置換されていてもよいベンゼン環であるか、(2)環Aが置換されていてもよいベンゼン環であり、環Bが置換されていてもよい単環不飽和異項環、置換されていてもよい二環縮合不飽和異項環、または置換されていてもよいベンゼン環であるか、または(3)環Aが置換されていてもよい二環縮合不飽和異項環であり、ここにおいて−NR−基および−CH−基は両方とも、当該二環縮合不飽和異項環の同じ環に結合し、環Bが置換されていてもよい単環不飽和異項環、置換されていてもよい二環縮合不飽和異項環、または置換されていてもよいベンゼン環であり、
    Rは水素原子、低級アルキル基、低級アルカノイル基または低級アルコキシカルボニル基である)
    で示される化合物、その医薬的に許容しうる塩、またはそれらのプロドラッグ
    ただし、N−[4−[(4−アミノ−3−クロロフェニル)メチル]−2−クロロフェニル]−β−D−グルコピラノシルアミンを除く。
JP2006519250A 2003-08-01 2004-07-30 新規化合物 Expired - Fee Related JP4717811B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49152303P 2003-08-01 2003-08-01
US60/491,523 2003-08-01
PCT/JP2004/011311 WO2005012321A1 (en) 2003-08-01 2004-07-30 Novel compounds

Publications (3)

Publication Number Publication Date
JP2007518682A JP2007518682A (ja) 2007-07-12
JP2007518682A5 true JP2007518682A5 (ja) 2007-09-20
JP4717811B2 JP4717811B2 (ja) 2011-07-06

Family

ID=34115512

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006519250A Expired - Fee Related JP4717811B2 (ja) 2003-08-01 2004-07-30 新規化合物

Country Status (18)

Country Link
US (1) US7521430B2 (ja)
EP (1) EP1654269B1 (ja)
JP (1) JP4717811B2 (ja)
KR (1) KR101101500B1 (ja)
CN (2) CN1829728A (ja)
AU (1) AU2004260760B2 (ja)
BR (1) BRPI0413233A (ja)
CA (1) CA2534022C (ja)
EA (1) EA011025B1 (ja)
ES (1) ES2527053T3 (ja)
IL (1) IL173051A (ja)
MX (1) MXPA06001273A (ja)
NO (1) NO333679B1 (ja)
NZ (1) NZ545305A (ja)
TW (1) TWI377209B (ja)
UA (5) UA86042C2 (ja)
WO (1) WO2005012321A1 (ja)
ZA (2) ZA200601686B (ja)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
TWI385177B (zh) * 2003-08-01 2013-02-11 Mitsubishi Tanabe Pharma Corp 吡喃葡萄糖基衍生物及其製造方法
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
AR053329A1 (es) * 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
TWI365186B (en) 2005-01-31 2012-06-01 Mitsubishi Tanabe Pharma Corp Indole derivatives
JP5073948B2 (ja) * 2005-01-31 2012-11-14 田辺三菱製薬株式会社 医薬組成物
TWI418556B (zh) * 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法
UY30730A1 (es) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
NZ577391A (en) * 2006-12-04 2011-11-25 Janssen Pharmaceutica Nv Thienyl-containing glycopyranosyl derivatives as antidiabetics
US7846945B2 (en) * 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
NO2200606T3 (ja) 2007-09-10 2018-03-24
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
MX2010012656A (es) 2008-05-22 2010-12-20 Squibb Bristol Myers Co Metodo para tratar la hiperuricemia empleando un inhibidor de sglt2 y composicion que contiene el mismo.
ES2380408T3 (es) 2008-08-28 2012-05-11 Pfizer Inc. Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
KR20110055740A (ko) * 2008-09-19 2011-05-25 노파르티스 아게 글리코시드 유도체 및 그의 용도
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
CA2767258C (en) 2009-07-10 2016-09-13 Janssen Pharmaceutica Nv Crystallisation process for 1-(.beta.-d-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl] benzene
JP5833011B2 (ja) * 2009-10-14 2015-12-16 ヤンセン ファーマシューティカ エヌ.ベー. Sglt2の阻害物質として有用な化合物の調製プロセス
NZ599945A (en) 2009-11-02 2014-05-30 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
HUE029853T2 (en) 2010-05-11 2017-04-28 Janssen Pharmaceutica Nv Pharmaceutical formulations containing 1- (beta-D-Glucopyranosyl) -2-thienylmethylbenzene derivatives as SGLT inhibitors
EP2697218B1 (en) 2011-04-13 2016-05-25 Janssen Pharmaceutica NV Process for the preparation of compounds useful as inhibitors of sglt2
US9035044B2 (en) 2011-05-09 2015-05-19 Janssen Pharmaceutica Nv L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
JP6173427B2 (ja) * 2013-02-26 2017-08-02 田辺三菱製薬株式会社 α−ハロテトラアシルグルコースの製造方法
CN103896930B (zh) * 2014-04-02 2016-08-17 安徽联创生物医药股份有限公司 卡格列净半水合物药用晶型的制备方法
ES2711804T3 (es) 2014-05-27 2019-05-07 Glenmark Pharmaceuticals Ltd Proceso para preparación de canagliflozina
CN104045673B (zh) * 2014-06-06 2017-01-18 安徽省食品药品检验研究院 双‑三氮唑缀合的假二糖衍生物及其制备方法
CN104478968A (zh) * 2015-01-14 2015-04-01 佛山市赛维斯医药科技有限公司 含噻唑基的o-半乳糖苷衍生物、其制备方法和用途
CN106188022A (zh) * 2015-04-30 2016-12-07 上海医药工业研究院 伊格列净的制备方法
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CA3105626A1 (en) 2018-07-19 2020-01-23 Astrazeneca Ab Methods of treating hfpef employing dapagliflozin and compositions comprising the same
US20220023252A1 (en) 2020-07-27 2022-01-27 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
US20240212818A1 (en) 2021-04-01 2024-06-27 Astrazeneca Uk Limited Systems and methods for managing prediabetes with a gliflozin sodiumglucose cotransport 2 inhibitor pharmaceutical composition
CN118510504A (zh) 2022-01-26 2024-08-16 阿斯利康(瑞典)有限公司 用于在治疗糖尿病前期或降低发展2型糖尿病的风险中使用的达格列净

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1075626B (de) * 1960-02-18 Farbwerke Hoechst Aktiengesellschaft vormals Meister Lucius &. Brunmg, Frankfurt/M Verfahren zur Herstellung von wasserlöslichen chemotherapeutisch wirksamen Glykosiden
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
EP1270584B1 (en) 2000-03-17 2005-12-07 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
EP1329456B1 (en) * 2000-09-29 2006-08-09 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
JP4212891B2 (ja) * 2000-11-30 2009-01-21 キッセイ薬品工業株式会社 グルコピラノシルオキシベンジルベンゼン誘導体、それを含有する医薬組成物およびその製造中間体
IL156678A0 (en) 2000-12-28 2004-01-04 Kissei Pharmaceutical Glucopyranosyloxypyrazole derivatives and use thereof in medicines
TWI255817B (en) * 2001-02-14 2006-06-01 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
US20030087843A1 (en) 2001-09-05 2003-05-08 Washburn William N. O-pyrazole glucoside SGLT2 inhibitors and method of use
DE102004048388A1 (de) * 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Similar Documents

Publication Publication Date Title
JP2007518682A5 (ja)
JP2008505194A5 (ja)
JP2007508362A5 (ja)
JP2005053931A5 (ja)
JP2007508359A5 (ja)
WO2007001975A8 (en) Piperidine derivatives useful as histamine h3 antagonists
JP2007523941A5 (ja)
JP2006526031A5 (ja)
JP2002543183A5 (ja)
JP2008546770A5 (ja)
JP2010536766A5 (ja)
JP2012510502A5 (ja)
JP2006515626A5 (ja)
JP2007523139A5 (ja)
JP2008514655A5 (ja)
EA200600348A1 (ru) Новые соединения
JP2006522035A5 (ja)
JP2007530525A5 (ja)
JP2005503385A5 (ja)
JP2008500997A5 (ja)
JP2010504286A5 (ja)
JP2008510828A5 (ja)
JP2007517826A5 (ja)
JP2009501704A5 (ja)
JP2009501745A5 (ja)